Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Should You Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down before the market opened on Monday . The stock had previously closed at $51.8050, but opened at $47.00. Zealand Pharma A/S shares last traded at $46.30, with a volume of 718 shares.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ZLDPF. Zacks Research lowered Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 13th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Finally, Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

The company’s 50-day moving average price is $47.03 and its two-hundred day moving average price is $47.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The company has a market capitalization of $3.38 billion, a P/E ratio of 7.84 and a beta of 0.88.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.